Besponsa (inotuzumab ozogamicin) Medical Drug Clinical Criteria
Customize your policy alerts
Sign up for Anthem Policy CC-0131 alerts
Get alerted when Policy CC-0131 changes without checking for updates manually.
Monitor payer policy activity
Clinical criteria governing prior authorization and medical necessity determinations for Besponsa (inotuzumab ozogamicin) use for CD22+ B-cell acute lymphoblastic leukemia (ALL), including frontline induction and relapsed/refractory settings; applies to Anthem members subject to medical benefit review.
Updated combination with TKI to specify Philadelphia chromosome-positive disease and clarified frontline therapy may be used with or without blinatumomab.
Removed ICD-10-CM D46.A and added C83.50-C83.59 to the coding list.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.